Jonathan Gardner
Senior Reporter | @ByJonGardner1118 articles by Jonathan Gardner
-
Trump revives pharma tariffs with 100% charges, but leaves loopholes
April 3, 2026 -
FDA approves Lilly obesity pill, triggering battle with Novo Nordisk
April 1, 2026 -
FDA, after turbulent year, leaves drugmakers guessing on its direction
April 1, 2026 -
Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout
March 31, 2026 -
Lilly’s AI commitment expands through deal with Insilico
March 30, 2026 -
AstraZeneca lung drug gets ‘surprise’ win in COPD trials
March 27, 2026 -
Merck’s deal for Terns sparks debate over a possible biotech bidding war
March 26, 2026 -
Karyopharm myeloma drug yields mixed data in myelofibrosis trial
March 24, 2026 -
Apogee strengthens case for longer-lasting eczema drug
March 23, 2026 -
Lilly’s three-pronged obesity drug hits goal in large diabetes trial
March 19, 2026 -
Bicycle to lay off 30% of staff, pivot away from Padcev challenger
March 17, 2026 -
Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial
March 16, 2026 -
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
March 12, 2026 -
Lilly unveils $3 billion production expansion in China
March 11, 2026 -
Roche’s prized breast cancer pill fails closely watched study
March 9, 2026 -
Vinay Prasad, controversial FDA leader, to again depart agency
March 6, 2026 -
FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
March 6, 2026 -
Lilly targets employers in new bid to broaden access to obesity drugs
March 5, 2026 -
Blackstone puts $400M into Teva, Sanofi gut disease drug
March 4, 2026 -
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
March 3, 2026 -
Roche pill succeeds in another MS study, but approval questions linger
March 2, 2026 -
Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial
Feb. 26, 2026 -
Alkermes’ Richard Pops to step down after three-decade run as CEO
Feb. 25, 2026 -
Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Feb. 23, 2026 -
Roche gets FDA decision date on closely watched breast cancer drug
Feb. 20, 2026